Hemochromatosis Panel Sanger Sequencing at Chughtai Lab

Hemochromatosis Panel by Sanger Sequencing (Out source Mayo clinic) at Chughtai Lab

Hereditary hemochromatosis is a highly prevalent autosomal recessive genetic disorder characterized by an abnormal increase in intestinal iron absorption. Over time, this systemic dysregulation leads to progressive iron deposition within vital parenchymal organs, including the liver, heart, pancreas, joints, and pituitary gland. If left untreated, the chronic accumulation of iron induces oxidative stress, lipid peroxidation, and cellular damage, culminating in severe clinical sequelae such as hepatic cirrhosis, hepatocellular carcinoma, dilated cardiomyopathy, cardiac arrhythmias, insulin-dependent diabetes mellitus, and debilitating arthropathy. The Hemochromatosis Panel by Sanger Sequencing (Out source Mayo clinic) at Chughtai Lab is a premier molecular diagnostic test designed to identify the primary genetic mutations responsible for this condition, specifically targeting the HFE gene.

Sanger sequencing remains the gold standard for targeted genetic analysis, offering unparalleled accuracy in detecting single nucleotide polymorphisms (SNPs) and small insertions or deletions. By analyzing the critical regions of the HFE gene, this panel provides definitive diagnostic confirmation for individuals suspected of having hereditary hemochromatosis. Chughtai Lab, a leading diagnostic network in Pakistan, facilitates this highly specialized molecular test by partnering with Mayo Clinic Laboratories in Rochester, Minnesota, USA. This international outsourcing model ensures that patients and clinicians in Pakistan receive world-class genetic testing, utilizing state-of-the-art sequencing technologies and expert clinical interpretation from one of the world's most prestigious medical institutions.

The clinical utility of this panel is profound. It allows for the early, pre-symptomatic identification of individuals at risk of iron overload, enabling timely therapeutic interventions such as therapeutic phlebotomy or iron chelation therapy. Furthermore, genetic confirmation eliminates the need for invasive diagnostic procedures, such as liver biopsies, in many clinical scenarios. By evaluating the HFE gene, this panel assists clinicians in establishing a precise diagnosis, formulating long-term management strategies, and conducting targeted familial screening to protect at-risk relatives.

Clinical Procedure: What to Expect

Patient Preparation

To ensure specimen integrity and accurate molecular analysis, patients must adhere to specific preparation guidelines prior to undergoing the Hemochromatosis Panel by Sanger Sequencing. Because this is a DNA-based genetic test, dietary intake does not directly affect the sequencing results. However, proper preparation is essential for a seamless sample collection process:

• No Fasting Required: Patients are not required to fast before this test. Normal dietary habits and hydration can be maintained.
• Medication Disclosure: It is imperative to inform the healthcare provider of all current medications, especially blood thinners (anticoagulants) or recent experimental gene therapies.
• Blood Transfusion History: Patients who have received a blood transfusion within the past three to four months must inform the laboratory, as donor DNA can temporarily interfere with genetic sequencing results.
• Hydration: Adequate oral hydration with water is highly recommended prior to the blood draw to facilitate easier venous access.
• Identification and Documentation: Patients must present valid identification and any relevant clinical history, family pedigree charts, or previous iron study reports at the time of sample collection.

During the Procedure

The sample collection process for the Hemochromatosis Panel is a standard venipuncture procedure executed under strict aseptic conditions by highly trained phlebotomists at Chughtai Lab:

• Patient Positioning: The patient is comfortably seated or reclined. The phlebotomist identifies a suitable vein, typically in the antecubital fossa of the arm.
• Aseptic Preparation: The skin over the selected vein is thoroughly cleansed with an antiseptic solution (such as 70% isopropyl alcohol) and allowed to air dry to prevent specimen contamination.
• Specimen Collection: A sterile, single-use needle is inserted into the vein, and a whole blood sample is collected into a lavender-top EDTA tube or a yellow-top ACD tube, as specified by Mayo Clinic Laboratories' strict specimen requirements.
• Post-Collection Care: The needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball or gauze pad to minimize hematoma formation. A protective bandage is then applied.
• Specimen Processing and Logistics: The collected blood sample is immediately inverted several times to ensure proper mixing with the anticoagulant. It is then logged into the laboratory information system, labeled with unique barcoded identifiers, and prepared for temperature-controlled international transport. Chughtai Lab maintains a rigorous cold chain protocol to preserve DNA stability during transit to Mayo Clinic Laboratories in the United States.

When is a Hemochromatosis Panel by Sanger Sequencing Performed?

Unexplained Elevated Iron Markers

Physicians routinely order this genetic panel when standard biochemical iron studies reveal persistently elevated markers of iron storage. Specifically, a transferrin saturation level exceeding 45% or a significantly elevated serum ferritin concentration in the absence of acute inflammation, infection, or malignancy warrants genetic investigation. The Sanger sequencing panel serves as the definitive secondary diagnostic step to determine whether these elevated biochemical markers are driven by an underlying genetic predisposition to hereditary hemochromatosis.

Family History of Hereditary Hemochromatosis

Because hereditary hemochromatosis is an inherited autosomal recessive disorder, first-degree relatives (siblings, parents, and children) of an individual diagnosed with HFE-associated hemochromatosis are at a significantly increased risk of carrying the disease-causing mutations. Genetic testing via this panel is highly recommended for family screening. Identifying carrier status or homozygous mutations in asymptomatic relatives allows for proactive monitoring of iron levels and early therapeutic intervention before clinical organ damage manifests.

Chronic Fatigue and Joint Pain of Unknown Origin

Chronic, debilitating fatigue and progressive, symmetric joint pain—particularly affecting the second and third metacarpophalangeal joints of the hands—are among the earliest, yet most non-specific, clinical presentations of hereditary hemochromatosis. When these symptoms remain unexplained after standard rheumatologic and metabolic evaluations, clinicians utilize the Sanger sequencing panel to rule out genetic iron overload as the primary underlying etiology, preventing years of diagnostic delay.

Unexplained Liver Dysfunction or Hepatomegaly

The liver is the primary storage organ for excess iron, making it highly susceptible to iron-induced toxicity. Patients presenting with unexplained hepatomegaly, persistently elevated liver transaminases (ALT and AST), or clinical signs of progressive liver disease (such as non-alcoholic fatty liver disease or unexplained cirrhosis) are prime candidates for this test. Confirming a genetic diagnosis of hemochromatosis helps differentiate iron-induced liver injury from other causes of chronic hepatitis and guides targeted therapeutic phlebotomy to halt hepatic fibrogenesis.

Multi-Organ Dysfunction and Bronze Diabetes

Advanced iron overload can manifest as a complex multi-organ syndrome, classically characterized by the triad of hyperpigmentation (bronze skin), diabetes mellitus (due to pancreatic islet cell iron deposition), and hepatomegaly. Additionally, patients may present with unexplained cardiomyopathy, congestive heart failure, cardiac arrhythmias, or hypogonadotropic hypogonadism (leading to erectile dysfunction or amenorrhea). In these complex clinical scenarios, the Hemochromatosis Panel by Sanger Sequencing is critical to confirm the genetic basis of the systemic disease and guide multi-disciplinary specialist care.

What Does a Hemochromatosis Panel by Sanger Sequencing Detect?

The Hemochromatosis Panel by Sanger Sequencing is highly specific and designed to detect a range of genetic variations, mutations, and clinical states associated with the HFE gene. This comprehensive molecular analysis detects:

• C282Y Homozygosity: The presence of two copies of the C282Y mutation, which is the primary genetic driver of classic Type 1 hereditary hemochromatosis.
• C282Y Heterozygosity: The presence of a single copy of the C282Y mutation, indicating carrier status.
• H63D Homozygosity: Two copies of the H63D mutation, which is generally associated with a milder risk of iron overload.
• H63D Heterozygosity: A single copy of the H63D mutation, representing carrier status.
• S65C Homozygosity: Two copies of the rarer S65C mutation, which may contribute to mild iron accumulation.
• S65C Heterozygosity: A single copy of the S65C mutation, indicating carrier status.
• Compound Heterozygosity (C282Y/H63D): The presence of one C282Y mutation and one H63D mutation, which can cause mild to moderate clinical iron overload.
• Compound Heterozygosity (C282Y/S65C): The presence of one C282Y mutation and one S65C mutation, representing a low-penetrance genotype.
• Compound Heterozygosity (H63D/S65C): A rare genetic combination with generally low clinical penetrance for iron overload.
• Wild-Type Genotype: The absence of any targeted mutations in the analyzed regions of the HFE gene, indicating a normal genetic profile.
• Novel Sequence Variants: Previously undescribed nucleotide substitutions within the targeted exons of the HFE gene.
• Intronic Splice-Site Mutations: Variations near exon-intron boundaries that may affect proper mRNA splicing of the HFE gene.
• Nonsense Mutations: Genetic alterations that introduce premature stop codons, resulting in a truncated, non-functional HFE protein.
• Missense Mutations: Single nucleotide substitutions that alter a single amino acid in the HFE protein structure.
• Silent Mutations: Synonymous nucleotide changes that do not alter the amino acid sequence or protein function.
• Genetic Predisposition Level: Categorization of the patient's genetic risk (high, moderate, low, or negligible) for developing clinical iron overload.
• Carrier Status for Family Planning: Identification of recessive carriers who may pass the mutated gene to their offspring.
• Atypical HFE Variants: Rare mutations within the HFE gene that lie outside the standard C282Y, H63D, and S65C loci.
• DNA Sequence Alignment: High-resolution comparison of the patient's DNA sequence against the standard human reference genome.
• Specimen Quality Metrics: Verification of DNA concentration, purity, and amplification success to ensure test validity.

Turnaround Time and Report Access at Chughtai Lab

Because the Hemochromatosis Panel by Sanger Sequencing requires specialized international shipping and analysis at Mayo Clinic Laboratories in Rochester, Minnesota, USA, the turnaround time is longer than standard local pathology tests. Typically, the comprehensive diagnostic report is completed and verified within 14 to 21 business days from the date of sample collection.

Chughtai Lab ensures that patients and referring physicians have seamless, secure, and rapid access to these critical genetic results. Once the verified report is received from Mayo Clinic, it is immediately uploaded to the Chughtai Lab secure database. Patients receive an automated SMS notification containing a direct link to download their electronic report. Reports can also be accessed anytime via the official Chughtai Lab mobile application or the online patient portal website. For those who prefer physical copies, high-quality printed reports can be collected from any Chughtai Lab diagnostic center across Pakistan.

Hemochromatosis Panel Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HFE Gene Exon 4 (C282Y)	Wild-type (No mutation detected)	Heterozygous (one copy) or Homozygous (two copies) C282Y mutation
HFE Gene Exon 2 (H63D)	Wild-type (No mutation detected)	Heterozygous (one copy) or Homozygous (two copies) H63D mutation
HFE Gene Exon 2 (S65C)	Wild-type (No mutation detected)	Heterozygous (one copy) or Homozygous (two copies) S65C mutation
Genotype Classification	Normal genetic profile (Wild-type)	Compound heterozygous (e.g., C282Y/H63D) or homozygous mutations
Clinical Iron Overload Risk	No genetically determined risk	Elevated to highly elevated risk of progressive systemic iron overload
Carrier Status	Non-carrier	Heterozygous carrier (can pass mutation to offspring)
DNA Sequence Quality	High-quality genomic DNA, successful amplification	Poor DNA yield, sample degradation, or PCR inhibition (requires redraw)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Hemochromatosis Panel?

• Mayo Clinic Collaboration: Direct outsourcing to Mayo Clinic Laboratories (USA) ensures world-class diagnostic accuracy and international standards.
• Rigorous Cold Chain Logistics: Strict temperature-controlled transport protocols preserve specimen integrity from Pakistan to the United States.
• Advanced Molecular Diagnostics: Access to cutting-edge Sanger sequencing technology for definitive genetic analysis.
• Convenient Home Sample Collection: Highly trained phlebotomists can collect your blood sample in the comfort of your home across major cities.
• Seamless Digital Access: Retrieve your genetic reports easily via the Chughtai Lab mobile app, website portal, or automated SMS links.
• National Presence: Conveniently located diagnostic centers throughout Pakistan, including Lahore, Karachi, and Islamabad.
• Professional Clinical Support: Dedicated customer care and clinical support teams to assist with test inquiries and logistics.
• Uncompromised Quality Control: Adherence to stringent international laboratory standards and external quality assurance programs.